Cameron N E, Cotter M A
Department of Biomedical Sciences, University of Aberdeen, Scotland, UK.
Diabetologia. 2001 May;44(5):621-8. doi: 10.1007/s001250051669.
AIMS/HYPOTHESIS: Increased oxidative stress has been causally linked to diabetic neurovascular complications, which are attenuated by antioxidants. There are several possible sources of reactive oxygen species in diabetes. Our aim was to assess the contribution of free radicals, produced by transition metal catalysed reactions, to early neuropathic changes. To this end, we examined, firstly, the effects of an extracellular high molecular weight chelator, hydroxyethyl starch-deferoxamine, which is expected to be confined to vascular space, on nerve perfusion and conduction deficits in diabetic rats and, secondly, the action of a single chelator dose.
Diabetes was induced by streptozotocin. In vivo measurements comprised sciatic nerve motor conduction velocity and endoneurial perfusion, monitored by hydrogen clearance microelectrode polarography.
We found that 8 weeks of diabetes reduced sciatic blood flow and conduction velocity by 48.3 % and 19.9% respectively. Two weeks of intravenous treatment corrected these deficits. Starch vehicle was ineffective. The time-course of action of a single hydroxyethyl starch-deferoxamine injection was examined in diabetic rats. There was a rapid increase in nerve blood flow on day 1, which remained within the non-diabetic range for 9 days before declining to the diabetic level at day 27. In contrast, conduction velocity changes were slower, reaching the non-diabetic range at day 6 and declining to the diabetic level at day 27.
CONCLUSION/INTERPRETATION: Extracellular transition metal catalysed reactions play a major role in the neurovascular deficits of experimental diabetes. Given the long-lasting effect of a single treatment, extracellular metal chelator therapy could be suitable for further assessment in clinical trials.
目的/假设:氧化应激增加与糖尿病神经血管并发症存在因果关系,抗氧化剂可减轻这些并发症。糖尿病中活性氧有多种可能来源。我们的目的是评估过渡金属催化反应产生的自由基对早期神经病变变化的作用。为此,我们首先研究了一种预期局限于血管空间的细胞外高分子量螯合剂羟乙基淀粉-去铁胺对糖尿病大鼠神经灌注和传导缺陷的影响,其次研究了单次螯合剂剂量的作用。
通过链脲佐菌素诱导糖尿病。体内测量包括坐骨神经运动传导速度和神经内膜灌注,通过氢清除微电极极谱法进行监测。
我们发现糖尿病8周后,坐骨神经血流量和传导速度分别降低了48.3%和19.9%。两周的静脉治疗纠正了这些缺陷。淀粉载体无效。在糖尿病大鼠中研究了单次注射羟乙基淀粉-去铁胺的作用时间进程。第1天神经血流量迅速增加,在9天内保持在非糖尿病范围内,然后在第27天降至糖尿病水平。相比之下,传导速度变化较慢,在第6天达到非糖尿病范围,在第27天降至糖尿病水平。
结论/解读:细胞外过渡金属催化反应在实验性糖尿病的神经血管缺陷中起主要作用。鉴于单次治疗的长期效果,细胞外金属螯合剂疗法可能适合在临床试验中进一步评估。